Literature DB >> 29630782

Acute toxicity of craniospinal irradiation with volumetric-modulated arc therapy in children with solid tumors.

Kenneth K Wong1,2, Omar Ragab1, Hung N Tran3, Anthony Pham1, Sean All4, Jonathan Waxer5, Arthur J Olch1,2.   

Abstract

BACKGROUND: Craniospinal irradiation (CSI) is an important part of curative radiation therapy (RT) for many types of pediatric brain or solid tumors. After conventional CSI, long term survivors may experience sequelae due to unintended dose to normal tissue. Volumetric modulated arc therapy (VMAT) CSI reduces off-target doses at the cost of greater complexity and error risk, and we describe our initial experience in a group of pediatric patients with solid tumors presenting with disseminated or recurrent disease. PROCEDURE: Pediatric patients with brain tumors were identified at Children's Hospital Los Angeles from 2013 to 2015. Clinical characteristics, acute toxicity, and radiotherapy data were abstracted from their medical records. We identified 19 patients who received VMAT CSI. Quality assurance was performed with a cylindrical detector array and ion chamber measurements at the arc junctions.
RESULTS: Patients had medulloblastoma or supratentorial primitive neuro-ectodermal tumor (n = 14, 11 high risk), germ cell tumors (two), relapsed neuroblastoma (two), and atypical teratoid/rhabdoid tumor (one). The most common acute toxicity was hematologic, including leukopenia (11% grade [Gr] 2, 26% Gr 3, and 63% Gr 4), anemia (89% Gr 2), and thrombocytopenia (16% Gr 1-2, 26% Gr 3, and 37% Gr 4). Despite leukopenia, we encountered only two Gr 3 infections (urinary tract and lung). The majority required blood products (89% red blood cells and 68% platelets). Weight loss was also common (47% Gr 1 and 26% Gr 2).
CONCLUSIONS: VMAT CSI, along with chemotherapy and anesthesia, is feasible with supportive care. Daily image-guided RT improves accuracy and reduces the risk of spinal cord overdose without increasing treatment time. Further research is needed to determine whether reducing doses to organs, such as thyroid, heart, or hippocampus, offsets the risk of increased volume of low-dose irradiation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CNS tumors; neuro-oncology; pediatric hematology/oncology; radiation oncology; radiation therapy

Mesh:

Year:  2018        PMID: 29630782     DOI: 10.1002/pbc.27050

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Encouraging early outcomes with image guided pencil beam proton therapy for cranio-spinal irradiation: first report from India.

Authors:  Utpal Gaikwad; M P Noufal; Jacinthlyn Sylvia; Ashok K Reddy; Pankaj Kumar Panda; Srinivas Chilukuri; Dayananda Sharma; Rakesh Jalali
Journal:  Radiat Oncol       Date:  2022-06-30       Impact factor: 4.309

2.  Toxicity and Clinical Results after Proton Therapy for Pediatric Medulloblastoma: A Multi-Centric Retrospective Study.

Authors:  Alessandro Ruggi; Fraia Melchionda; Iacopo Sardi; Rossana Pavone; Linda Meneghello; Lidija Kitanovski; Lorna Zadravec Zaletel; Paolo Farace; Mino Zucchelli; Mirko Scagnet; Francesco Toni; Roberto Righetto; Marco Cianchetti; Arcangelo Prete; Daniela Greto; Silvia Cammelli; Alessio Giuseppe Morganti; Barbara Rombi
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

3.  Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma.

Authors:  Clemens Grassberger; Daniel Shinnick; Beow Y Yeap; Mark Tracy; Susannah G Ellsworth; Clayton B Hess; Elizabeth A Weyman; Sara L Gallotto; Miranda P Lawell; Benjamin Bajaj; David H Ebb; Myrsini Ioakeim-Ioannidou; Jay S Loeffler; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-02-05       Impact factor: 8.013

4.  Assessment of the results and hematological side effects of 3D conformal and IMRT/ARC therapies delivered during craniospinal irradiation of childhood tumors with a follow-up period of five years.

Authors:  Zoltán Lőcsei; Róbert Farkas; Kornélia Borbásné Farkas; Klára Sebestyén; Zsolt Sebestyén; Zoltán Musch; Ágnes Vojcek; Noémi Benedek; László Mangel; Gábor Ottóffy
Journal:  BMC Cancer       Date:  2020-07-29       Impact factor: 4.430

5.  Pulmonary toxicity of craniospinal irradiation using helical tomotherapy.

Authors:  Joongyo Lee; Euidam Kim; Nalee Kim; Chang-Ok Suh; Yoonsun Chung; Hong In Yoon
Journal:  Sci Rep       Date:  2022-02-25       Impact factor: 4.379

Review 6.  Cardiotoxicity of mediastinal radiotherapy.

Authors:  Ivica Ratosa; Maja Ivanetic Pantar
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-30

Review 7.  Preclinical Models of Craniospinal Irradiation for Medulloblastoma.

Authors:  Jennifer L Stripay; Thomas E Merchant; Martine F Roussel; Christopher L Tinkle
Journal:  Cancers (Basel)       Date:  2020-01-05       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.